Key result
Anti-Ku myositis linked to fatal inflammatory myocarditis with LVEF declining to 12% despite aggressive immunosuppression.
Why the study?
Anti-Ku antibodies often signal multisystem involvement in overlap myositis, but overt heart failure is seldom reported.
Case Report (n=1)
Anti-Ku myositis can present with aggressive cardiac involvement and may be refractory to conventional immunosuppression once advanced cardiomyopathy is established.
Answers are grounded in this paper and cite their sources.
Highlights potential fatality in anti-Ku myocarditis despite immunosuppression; leaves open role of early antibody screening.
Background Anti-Ku antibodies are rare disease of overlap myositis and often signal multisystem involvement. Overt heart failure, however, is seldom reported. Case summary A 60-year-old man presented with progressive exertional dyspnoea and chest tightness. Initial echocardiography showed mildly reduced left-ventricular ejection fraction (LVEF 49%), and coronary angiography was normal, leading to a diagnosis of MINOCA. One month later he re-presented with worsening breathlessness, dysphagia, and proximal muscle weakness. Laboratory tests revealed serum creatine kinase 2,680 IU/L, troponin I 928 ng/L, and pro-BNP 1,049 ng/L. Repeat echocardiography demonstrated dilated ventricles and LVEF 35%. During admission he developed High grade AV dissociation requiring dual-chamber pacing and abrupt thrombocytopenia. Cardiac MRI identified a diffuse infiltrative pattern with LVEF 18%. Myositis-specific immunoblot detected high-titre anti-Ku antibodies, and deltoid biopsy confirmed inflammatory myopathy. Despite high-dose corticosteroids, mycophenolate, cyclophosphamide, and intravenous immunoglobulin, cardiac function deteriorated to LVEF 12%. Recurrent aspiration pneumonia necessitated gastrostomy. Eight months after initial presentation the patient died following transition to palliative care. Conclusion This case illustrates (i) the propensity of anti-Ku myositis for aggressive cardiac involvement, (ii) diagnostic delay when heart disease precedes overt muscle symptoms, and (iii) limited efficacy of conventional immunosuppression once advanced cardiomyopathy is established. Early autoimmune testing—including myositis panels—in patients with unexplained cardiomyopathy plus systemic features may avert missed therapeutic window.
No takes yet. Share an insight, caveat, or question.
ELBekiey et al. (2026) conducted a case report in Anti-Ku myositis with progressive inflammatory myocarditis (n=1). Anti-Ku myositis was evaluated on Cardiac function and survival. Anti-Ku myositis in a 60-year-old man led to fatal progressive inflammatory myocarditis, with left ventricular ejection fraction declining from 49% to 12% despite aggressive immunosuppression.
Synapse has enriched 10 related papers. Consider them for comparative context: